NTRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Buy now for a tactical dip-entry: price (197.6) is extremely oversold (RSI_6 ~6.96) and sitting just above S2 support (194.7), which often sets up a sharp rebound.", "Fundamentals and Street view remain strongly supportive (multiple recent Buy/Overweight reiterations with raised targets up to $300), providing a favorable medium-term backdrop.", "Near-term sentiment is fearful (put volume surge), which can coincide with capitulation and bounce potential; however, trend is still down, so the \u201cedge\u201d here is the oversold + support setup."]
["Trend/Momentum: Bearish in the near term \u2014 MACD histogram (-4.41) is below zero and negatively expanding, indicating downside momentum is still building.", "Oversold: RSI_6 at 6.96 signals an extreme oversold condition (mean-reversion/bounce setup).", "Levels: Current price (197.6) is near S2 (194.704). A clean hold above ~194.7 supports a bounce thesis; upside reference levels are S1 (206.526) then Pivot (225.66).", "Moving averages: Converging MAs suggest the prior trend is losing coherence, but not yet confirming a reversal."]
["Regulatory/clinical catalyst: FDA premarket approval application submitted for Signatera CDx for MRD detection in bladder cancer after successful trial results (supports MRD expansion narrative).", "Institutional flow: Hedge funds buying increased ~265.7% over the last quarter (supportive demand signal).", "Upcoming catalyst: QDEC 2025 earnings on 2026-02-26 after hours could re-rate shares if growth/margins continue to improve."]
["Price action risk: Current momentum is bearish (MACD expanding negative), so the stock can keep sliding even while oversold.", "Options tape is defensive: Put volume dominates today (volume put/call 3.65), implying traders are positioned for further near-term downside or hedging aggressively.", "Near-term probabilities (pattern-based): Similar-pattern stats imply muted near-term drift (next day/week roughly flat), reducing immediate follow-through confidence."]
["Latest quarter (2025/Q3): Revenue $592.2M, +34.66% YoY \u2014 strong top-line growth.", "Profitability improving: Net income -$87.5M (loss narrowing; +177.11% YoY improvement) and EPS -0.64 (+146.15% YoY improvement).", "Margins: Gross margin 64.91%, +5.05% YoY \u2014 indicates improving unit economics and scaling benefits."]
["Recent trend: Clear upward bias \u2014 multiple firms raised price targets from mid-Nov 2025 through early Jan 2026 while maintaining Buy/Overweight stances (targets commonly $260-$300).", "Wall Street pros: Dominant position and runway in MRD (Signatera) and strong organic growth profile; diagnostics/tools setup viewed favorably into 2026.", "Wall Street cons: Not unanimous \u2014 at least one notable Equal Weight (Wells Fargo) suggests some valuation/expectations are already embedded despite strong fundamentals.", "Net take: Street sentiment is predominantly bullish and increasingly confident (rising targets), supporting a buy-the-dip decision here."]
